Investigational New Drugs
Overview
Investigational New Drugs is a peer-reviewed scientific journal that focuses on the development and evaluation of novel therapeutic agents for the treatment of various diseases. It publishes cutting-edge research articles, reviews, and clinical trials, providing valuable insights into the discovery and development of innovative drugs. The journal serves as a platform for researchers, clinicians, and pharmaceutical professionals to share their findings and contribute to the advancement of drug discovery and development.
Details
Details
Abbr.
Invest New Drugs
Publisher
Springer
Start
1983
End
Continuing
Frequency
Quarterly
p-ISSN
0167-6997
e-ISSN
1573-0646
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 3275
97
SJR / Ranks: 3293
1086
CiteScore / Ranks: 3060
6.80
JIF / Ranks: 2884
3.4
Recent Articles
1.
Wu Z, Lei H, Li R, Liu X, Wang C
Invest New Drugs
. 2025 Mar;
PMID: 40063183
Immune encephalitis (IE) is an immune-mediated adverse events (irAEs) linked to nivolumab therapy, and its clinical characteristics remain unclear. This study aimed to analyze the clinical patterns of nivolumab-induced IE...
2.
Johnson M, Hong D, Brana I, Schoffski P, Galvao V, Rangwala F, et al.
Invest New Drugs
. 2025 Mar;
PMID: 40042547
SL-279252 is a bifunctional hexameric fusion protein adjoining the extracellular domains of PD-1 and OX40L via an inert IgG4 derived Fc domain. A Phase 1 dose escalation study was conducted...
3.
Gupta S, Sharma A, Shukla A, Mishra A, Singh A
Invest New Drugs
. 2025 Feb;
PMID: 40014234
Over the past decade, Bruton's tyrosine kinase (BTK) has emerged as a pivotal therapeutic target for B-cell malignancies and autoimmune diseases, given its essential role in B-cell development and function....
4.
Pan Y, Li W, Wu Z, Sun W, He B, Wang C
Invest New Drugs
. 2025 Feb;
PMID: 39994086
To study the clinical features of nivolumab-induced immune-related pancreatitis and to provide evidence for its recognition and treatment. Cases of nivolumab-induced pancreatitis were collected by searching Chinese and English databases...
5.
Huang H, Zhou Y, Shang C, Zhang Y, Shen Y
Invest New Drugs
. 2025 Feb;
PMID: 39982632
HER2 and EGFR are frequently co-expressed in various tumors. While antibody-drug conjugates (ADCs) targeting HER2, such as T-DM1 and T-Dxd, have shown remarkable antitumor effects in clinical responses, their effectiveness...
6.
Thein K, Karp D, Tsimberidou A, Gong J, Sulovic S, Shah J, et al.
Invest New Drugs
. 2025 Feb;
PMID: 39976873
No abstract available.
7.
Liu D, Gong J, Zhang J, Shu Y, Wu H, Liu T, et al.
Invest New Drugs
. 2025 Feb;
PMID: 39976872
RMX1002 (grapiprant) is a selective E-type prostanoid receptor 4 (EP4) antagonist and a promising candidate for cancer therapy, potentially enhancing anti-tumor immune responses. This study aimed to evaluate the safety,...
8.
Li H, Shen X, Chu Y, Yuan P, Shuai Q
Invest New Drugs
. 2025 Feb;
PMID: 39966300
Research on prodrug technology has opened new avenues for site-directed chemotherapy rather than systemic chemotherapy. This distinctive strategy allows drug delivery to be activated by light-, irradiation-, or ultrasound (US)-tunable...
9.
Kim J, Han J, Kwon J, Kim M
Invest New Drugs
. 2025 Feb;
PMID: 39962008
Poly(ADP-ribose) polymerase (PARP) inhibitors may have cardioprotective properties. This study aimed to evaluate the potential cardioprotective effects of PARP inhibitors in patients with epithelial ovarian cancer treated with platinum-based chemotherapeutic...
10.
Yang P, Li Y
Invest New Drugs
. 2025 Feb;
PMID: 39956882
Colorectal cancer is the third most prevalent cancer in the world. Early screening and detection of tumours, active surgical radical treatment, postoperative adjuvant chemotherapy, targeted therapy, and immunotherapy are performed...